Get the Stockscreener App
1.2801
0.01%
0.000100
Plus Therapeutics Inc Stock (PSTV) Latest News
Glioma Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight - EIN News
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - Yahoo Finance UK
Leptomeningeal Metastases Pipeline Analysis, Clinical - openPR
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight - The Globe and Mail
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA - openPR
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal - STAT
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, - openPR
Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review - Defense World
Are Broader Antibody Patents Possible in US Through Means-Plus-Function Claiming? - JD Supra
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics - STAT
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Roche Launches $9/Share Cash Tender Offer for Poseida Therapeutics, CVR Could Add $4 More - StockTitan
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan
Key Drivers of AI Drug Discovery - Genetic Engineering & Biotechnology News
HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World
Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network
Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan
PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan
PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire
Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan
Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire
Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan
Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - STAT
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com
Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus: Q3 Earnings Snapshot - New Haven Register
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Plus Therapeutics Advances Cancer Drug Pipeline, Reports $4.4M Grant Revenue in Q3 | PSTV Stock News - StockTitan
Roche teams up with transcription factor trailblazer Flare in new $1.8B-plus cancer pact - Fierce Biotech
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India
Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):